Recent News

• 12.04.2025 - Stanford Medicine’s Dr. Pejman Ghanouni Receives RSNA’s Cum Laude Award for CAPTAIN Perioperative Data Presentation
• 11.28.2025 - Profound Medical to Launch AI-Powered BPH Module, Present New TULSA-PRO® Clinical Data, at RSNA and SUO Meetings
• 11.18.2025 - Profound Medical Celebrates The Hong Center’s 200th Independent TULSA Procedure for Prostate Disease
• 11.13.2025 - Profound Medical Reports Strong Third Quarter 2025 Financial Results
• 11.12.2025 - Profound Medical Announces Strategic Distribution Agreement with Getz Healthcare to Bring TULSA-PRO® to Australia and New Zealand
• 11.11.2025 - Profound Medical Inks Exclusive Distribution Agreement for TULSA-PRO® and Sonalleve® with Al Faisaliah Medical Systems in Saudi Arabia
• 11.10.2025 - Profound Medical Regains Exclusive Distribution Rights for TULSA-PRO® in Canada from Knight
• 10.16.2025 - Profound Medical Congratulates the Busch Center for Achieving 500th TULSA Procedure Milestone
• 10.14.2025 - Profound Medical to Participate in the Stifel 2025 Healthcare Conference
• 10.07.2025 - Profound Medical Achieves Record Preliminary Unaudited Revenue for the 2025 Third Quarter

Recent Filings

• 11.28.2025 - EX-99.1 EX-99.1
• 11.28.2025 - 8-K Current report
• 11.13.2025 - S-3 Registration statement under Securities Act of 1933
• 11.13.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.12.2025 - 8-K Current report
• 11.12.2025 - EX-99.1 EX-99.1
• 11.12.2025 - EX-99.1 EX-99.1
• 11.12.2025 - 8-K Current report
• 11.12.2025 - EX-99.1 EX-99.1
• 11.12.2025 - 8-K Current report